Abstract
Local progressive tumor growth involving the urinary tract with no distant metastases is known to be one of the features of cervical cancer in the advanced stages. Approximately 68 % of patients in stage T3-T4 have various uroevolution disorders. The severity of their condition often is caused by an increasing renal failure or a fever, those are associated with obstructive pyelonephritis and often are interpreted as the carcinogenic intoxication. Therefore, any special antineoplastic therapy methods are considered as unpromising even for patients without concomitant diseases. The authors conducted a retrospective analysis of 11 patients with the treatment of advanced non-metastatic cervical cancer, which included both surgery and neoadjuvant polychemotherapy (PCT). Our results demonstrate the advisability of multimodal phasing treatment of those patients, compared with palliative radiotherapy and symptomatic treatment.
Highlights
hyperplastic forms of chronic sinusitis are accompanied by depression of cell immune response and activation
The cytosine in position 511 of the promoter zone of ІL-1β-gene aggravates the suppression of the cell-link of immunity response
a deficit of factors of nonspecific resistance in case of chronic exudative sinusitis while thymine in position 590 of promoter zone of ІL-4-zone increases the deficit of factors of non-specific resistance
Summary
The immune disturbances in exudative and hyperplastic forms of chronic sinusitis are accompanied by depression of cell immune response and activation of the humoral one; by a deficit of the factors and mechanisms of nonspecific resistance of organism. МУЛЬТИМОДАЛЬНЕ ЛІКУВАННЯ ХВОРИХ ІЗ ПРОГРЕСУЮЧИМ РАКОМ ШИЙКИ МАТКИ Що однією з особливостей раку шийки матки (РШМ) на пізніх стадіях є місцевий прогресуючий ріст із залученням у пухлинний процес сечових шляхів при відсутності віддалених метастазів. До 68 % таких хворих на стадії Т3-Т4 мають ті чи інші порушення уродинаміки.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
